is... money hunting
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Researching and learning more about this, a vaccine is for the healthy but will not help if you are already infected. An antiviral is for those who are already sick. So that means Ampligen is needed right now and Ampligen, a prophylactic antiviral, is ready to go now, safe and very effective in SARS.100% survival rate taking AIM’s drug Ampligen while infected with SARS, which is almost identical to COVID-19 in critical areas for treatment.
Also, Vaccine: prevent or mitigate infections. They are designed to induce a protective immune response in the body against the viruses represented in the vaccine. When vaccinated, the immune system of the body produces a specific response, consisting of specific T cells and specific antibodies that fight off the infection when exposure to the virus occurs at a later stage. More importantly, vaccination also leads to the induction of a specific immunological memory against the viruses represented in the vaccine. Upon contact with the virus at a later stage, the immune system is able to mount a specific response much more rapidly than the non-primed immune system.
...understanding this better Ampligen would need to do this to be a vaccine and I can’t find anything on SARS that it had done this, so I’m going to roll out that Ampligen could be a Vaccine now and is a antiviral with great efficacy.
When news of testing comes back we will know if Ampligen is a vaccine for COVID-19, an effective prophylactic antiviral or isn’t effective for use on COVID-19. I find it a high probability Ampligen is very effective and a possible vaccine, because of the facts/data available on animal testing specifically catered to replicate humans. Results were 100% survival rate of SARS infected mice using Ampligen and 100% death rate of the SARS infected mice who were not treated with Ampligen. Key info here, SARS is almost identical in critical pathogenic RNA frames as COVID-19 for this antiviral to work. Also a lot of testing has been done with humans taking Ampligen for cancer or chronic fatigue syndrome and Ampligen is very safe for humans. Ampligen is way ahead of anyone else and has already been way ahead of anyone else for SARS, is ready to go created/tested, is extremely safe and protective for humans.
I want Ampligen available to my family. We need to fast track this drug! Things are bad already and it’s just beginning. Coronavirus has just begun to unfold. Ampligen is proven to be absolutely safe, protective and a very effective antiviral against an almost identical virus , SARS, in the key pathogenic RNA frames. This drug would save a lot of people’s lives. There’s been enough Death, let’s deploy Ampligen Worldwide and put an end to COVID-19!
As wrong as you can get about AIM’s drug. Ampligen is a prophylactic antiviral that is very safe and very effective against SARS, 100% effectiveness and survival rate for infected who took the drug. SARS is almost identical in critical pathogenic RNA frames as Wuhan coronavirus or COVID-19. Ampligen is being distributed to China through an entity working with the government and being human tested in Japan with testing led by the director of WHO.
This is a good video AIM’s CEO took the time to put out. It describes what Ampligen can do for the world and why it is effective against COVID-19. The video also explains a brief summary in what AIM does and what they have in the pipeline. An informative video for new watchers, investors or if you just haven’t watched it yet, to get an idea of what exactly you are investing in. I like how you get the feeling and can tell the CEO generally wants to help.
Light volume PM but it’s looking good and setting up nice. Either way AIM is farther ahead, have the safest drug, and most effective; having a drug for a treatment where 100% of the patients survived because of the drug. Proven effectiveness because 100% of the patients that did not take AIM’s drug, Ampligen, died. This is the stock I’m investing in for a real move, when news that Japan is going to use Ampligen because of successful testing running as we speak... which is guided by the director of WHO.
Ampligen is AIM’s drug.... During ampligen trials on mice infected with SARS, 100% of the mice that received Ampligen survived while 100% of the mice that did not receive Ampligen died. COVID-19 is now formally SARS-COV-2 and has a similar makeup to SARS. Hopefully, while Ampligen is being tested on infected humans in Japan, it will show the same results as it did on SARS in the trials.
Joshua Rodriguez. founder of Alpha Stock News and CNA Finance: “$AIM could be sitting on a figurative goldmine!”
https://alphastocknews.com/aim-immunotech-aim-stock-rockets-heres-why/2701/
I’m betting AIM will receive a chunk out of this package...
https://www.reuters.com/article/us-healthcare-coronavirus-japan-package/japan-to-unveil-package-vs-new-virus-not-yet-considering-extra-budget-idUSKBN20X04B?feedType=RSS
Is there any short shares available? That’d mean this rose on profit takers selling to buyers. Imagine the short squeeze coming. Hold.
iBio opened ten years ago with a federal grant to establish facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic.
FastPharming Technology has been used to produce antibody candidates for Ebola and Dengue fever viruses, yellow fever virus, human papilloma virus, seasonal influenza and avian influenza.
The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas.
iBio acquired Caliber’s facility in early 2016. The building is in the Brazos Valley’s Biocorridor, which runs along the College Station!
Part of the reason the Brazos Valley was chosen to be home to the facility was the proximity to Texas A&M University, its research and its talent. In fact, a primary focus of iBio is hiring people trained locally.
Talks about the potential spike protein subunit vaccine. IBio and their CC-pharming partnership are working on a subunit protein vaccine.
https://link.springer.com/article/10.1007/s00134-020-05985-9
I’m not bashing the company, by all means, on my recent posts. I’m just trying to understand what’s going on here and why I think the company is undervalued, but the stock price has been going down. I’ve came to a conclusion and figured out why from my own experience, DD and speculation. A further discussion on the topic and more insight on everything from experienced investors, is why I posted it all here. Lets face it, you’re not moving the price by trying to sell or bash this company. The ones moving the stock price already know what’s going on and are making their investments accordingly. Yes, I do like the reassurance and confidence of the positive people on this board, for my own investment in ALPP, but why can’t we talk about what’s really going on, facts, more involved discussions on everything, our thoughts and anything to help one another understand the many things going on with this company. So that we are smartly investing our money, on a period of time we are willing to. The market is always right, you will lose trying to fight it.
No one is holding this down. I am long and was pumping the company as much as anyone but ALPP has made moves that resemble a failing desperate company, after I thought things were turning around and looking so good for ALPP. I do not believe this to be the case for ALPP but there was no reason to seek out and ink a funding deal that has proven to be death spirals for other companies historically. I was just in a stock with an LPC like ATM tap. You realize LPC takes on no risk? As soon as ALPP tells them to buy shares, LPC sells them directly back into the market. Now we are fighting dilution on top of everything else. I want ALPP to become what it could be as much and badly as anybody but investors know what these kinds of deals are and what it does to a stock. They are last chance efforts to make payments, pay overhead, pay debt, and then, try to turn the company around before they are delisted or bankrupt but usually end up in renewing another and another ATM tap lending deal going into a death spiral and mass diluting the shares. This could definitely be a different outcome with ALPP, seeing their growth and revenues, but I do not like that they signed a deal like this and I’m sure many other investors don’t either. Especially since ALPP is carrying debt and just announced, making it clear they are thinking about, an R/S. These are 3 factors, that if they are done together, they are heavily weighted by investors and are hurting us badly on ALPP’s stock.
LPC deal and R/S mention is hurting us. If ALPP up-lists it’ll have to be from a big R/S for soon or big moves and won’t be soon. ALPP should of paid off debt before trying to up-list. Too much uncertainty with everything going on, for someone to move the price to invest here.
“Sleeping Giant: Why iBio Uses Plant Based Therapeutics
One of the reasons why iBio uses a plant based protein model is because it has efficacy advantages over similar antibodies. iBio scientists engineer vectors for the desired protein sequence and transfer them to agrobacteria, which infiltrate mature plants and transfer the gene to the plant cell nuclei, which over the course of about five days churn out the therapeutic protein.
Downstream steps are similar to purification of proteins expressed in mammalian cells.
iBio employs transient transfection, meaning that the agrobacterium hijacks the plant’s protein without conferring permanent changes to the plant’s genetics—the plant cannot pass protein production capability on to offspring.
Thus, issues related to human consumption of genetically modified plants disappears, as does the potential for Frankenplant-type scenarios in which traits are transmitted willy-nilly to plants outside the production area. “FDA views the plants as a raw material,” says iBio CEO Robert Erwin.
iBio conducts its cGMP processes indoors for biopharmaceuticals, but applications are opening up for producing food or industrial proteins outdoors.
Like all genetic engineering, transient transfection requires getting genes into cells in some manner. Spraying the transfected agrobacterium onto plants works, but iBio has devised a much more efficient, and elegant technique. It submerges plants into a suspension of the bacterium, and applies a vacuum to remove gases lurking within the plant structure. Releasing the vacuum creates a positive relative pressure that forces agrobacterium into cells via interstitial openings.”
https://stockpence.com/featured/coronavirus-ibio-sleeping-giant/
Someone correct me if I’m wrong but the way I understand it, IBIO does not develop anything. They manufacture and have the ability to manufacture 100 Million doses of vaccine a month. They are currently partnered with CC Pharma and are not restricted. They can enter a relationship with any vaccine developer they want. In the largest vaccine manufacturing facility in the world, in Brady, TX and was funded by DARPA years ago. A note on IBIO’s partnership already with CC Pharma, if they have any kind of vaccine progress. CC Pharma does not have to go through phases and trails like in the USA and can, most likely will, go directly into human testing to create a faster vaccine.
.....so seems like a good investment to me and it pulled back and is consolidating. Being that IBIO can partner and manufacture a vaccine on a large scale deployment with anyone who creates a vaccine but already has one partner to do it for as of now, IBIO definitely doesn’t seem like it’s too late to get in on now. Actually seems getting in now would be early or great time, to not chase and compound the most gains from when it blows through the roof.
What’s the back story on why IBIO was at so low of a stock price not too long ago?
Combat COVID-19 with FastPharming. This company is able to pump out a vaccine fast and able to handle a large scale deployment.
https://www.ibioinc.com/
Where’s the volume?
Is that a pennant flag I’m seeing on the 1 hr? Up up up. Looking like a good day tomorrow. Market is liking the 8K.
Real time detection of who you are regardless of whether mask wearing or not and temperature management. pic.twitter.com/uqAYxxOGpz
— Remark Holdings (@RemarkHoldings) March 3, 2020
Fed cutting rates is good news for MARK and they have a PR out. Holding support and consolidating well. Come on, let it fly.
Anybody know the authorized shares?
Awesome find and great DD. Looks like if you follow the connections, there is a lot more to MARK than meets the eye.
Privately held Sharecare, Remark Holdings (MARK) owns about 4.5% of, announced Quest Diagnostics (DGX) as its preferred laboratory partner; Quest also making a strategic investment in the company, 14B investment. This could mean an IPO going forward. Based on current analysis, estimation value of Remark's stake is worth about $150M-$175M, implying about $3.65-$4.31/share, multiples of (MARK)’s current $32M marketcap value. A liquidity event in Sharecare would help to much better capitalize (MARK)'s AI business, and would rid any uncertainty for investors to start heavily investing in (MARK). Causing a huge move up in (MARK)’s price per share. Just valuation alone should cause a correction to a much higher share price, let alone current contracts, upcoming news, contracts and business moves.
If MARK would start blipping on the radar for tech that can be used to screen for Coronavirus, this would break out and jump up too. Any kind of news that the company is in works of a deal or contract for Coronavirus specifically, would cause a nice move right now. As this is just the start of the infectious spread becoming worse, a lot of countries infected with it being just recently, so there is a lot more spread/sickness to occur and not many countries left before WHO declares this a pandemic. A tool that MARK has, implemented to screen for people to help determine if they have elevated body temps and should be screened for coronavirus infection for faster containment, could be very useful worldwide. I do not think just the fact or news that MARK is able to do it is enough though, maybe, but I think it’s going to take actual evidence there is demand of the product specifically for Coronavirus or actual implementation. We will see what happens here but regardless , MARK is valued cheap compared to their market cap and current contracts and I think we are going higher. It’s all just a matter of time and/or events that happen.
Could be waiting for them to monetize their 4.5% stake in Sharecare within the next 60 days.
The funds to finance their pipeline of projects, would take away any uncertainty for big new investors and shareholders. “Buy the fear, sell the greed”.. If you’re in now before the chase, you’ll be sitting pretty on your gains once this is finally let up. Looks like a big squeeze imminent and it’s going to climb fast.
Two more of our #AI papers have been pre-selected by
@CVPR the premier annual #ComputerVision event. Congrats to Dr. Yang ( $MARK R&D head and his team)
Two more of our #AI papers have been pre-selected by @CVPR the premier annual #ComputerVision event. Congrats to Dr. Yang ( $MARK R&D head and his team) pic.twitter.com/oeFmJm2eFM
— Remark Holdings (@RemarkHoldings) February 28, 2020
Someone tell the company, now is time to release a PR. Perfect opportunity, what are they waiting for?
When is the first stop of the road show supposed to happen or around when should we see the first purchases from the road show? Also how can you buy C shares? As I might be interested in holding till at least 2022 and start a position there, along with the position I have now. Thanks in advance.
It’s got to the point where when I look at ALPP’s price per share and all I see is stacks of cash. I’ve never found a stock like this that has been flying under the radar and is a completely legit successful company growing and growing, doing almost 100% better than the previous year. Acquiring businesses to grow and is at a point where they have no dilution and could outright buy the next acquisition ALPP has their eye on. Already has funding locked in to go to Nasdaq. Has less OS + A/S, float, makes more revenue than most of OTC and Nasdaq already and is so undervalued.
I know, I know, but I’m still making money every 2 weeks and I can’t bear to put it anywhere else but in ALPP . I guess nothing good comes from being greedy, I’ll just keep buying ALPP the whole way up and catching every dip I can. Really don’t even need to worry about what the price is or penny pinching buying at the bid because we are going up. Just buy buy buy and profit $$$
Can this please go back to $0.12!? I’m not done buying yet. Everyone complaining or who don’t believe, why don’t you just sell and invest in something you feel confident in. So I can buy your shares. Why don’t I slap the ask, well because I’m not in a rush for this to go higher and want to accumulate more shares. I know it’s going to far greater heights that’s why I’m investing.
This is amazing news. I love the ceo of this company! What a trustworthy, hard working, stand up guy. Only downfall is I was waiting for funds to clear and didn’t get to purchase more shares before close. I hope I can buy more before ALPP goes up.